Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. Februar 2025 16:30 ET
|
Olema Oncology
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology to Participate in Upcoming Investor Conferences
03. Februar 2025 16:30 ET
|
Olema Oncology
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. Januar 2025 16:30 ET
|
Olema Oncology
SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
02. Januar 2025 07:00 ET
|
Olema Oncology
SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
10. Dezember 2024 07:00 ET
|
Olema Oncology
Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with...
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
09. Dezember 2024 07:00 ET
|
Olema Oncology
Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. Dezember 2024 16:30 ET
|
Olema Oncology
SAN FRANCISCO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
02. Dezember 2024 07:00 ET
|
Olema Oncology
Clinical trial collaboration and supply agreement enables pivotal Phase 3 OPERA-02 clinical trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer; trial...
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
25. November 2024 17:30 ET
|
Olema Oncology
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
12. November 2024 16:01 ET
|
Olema Oncology
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on...